RNA epigenetic modifications in ovarian cancer: The changes, chances, and challenges

Ye, Lele; Yao, Xin; Xu, Bin; Chen, Wenwen; Liang, Han; Tong, Xinya; Su, Fang; Zou, Ruanmin; Hu, Yingying; Wang, Zhibin; Xiang, Dan; Lin, Qiaoai; Feng, Shiyu; Xue, Xiangyang; Guo, Gangqiang

doi:10.1002/wrna.1784

Cited by 8 publications

(2 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian cancer is the fourth most common cancer of female worldwide [156]. Abundant of researches have showed that SULF1 is a known suppressor in ovarian cancers [157].…”

Section: Ovarian Cancermentioning

confidence: 99%

6-O-endosulfatases in tumor metastasis: heparan sulfate proteoglycans modification and potential therapeutic targets

Han

2024

Am J Cancer Res

View full text Add to dashboard Cite

Metastasis is the leading cause of cancer-associated mortality. Although advances in the targeted treatment and immunotherapy have improved the management of some cancers, the prognosis of metastatic cancers remains unsatisfied. Therefore, the specific mechanisms in tumor metastasis need further investigation. 6-O-endosulfatases (SULFs), comprising sulfatase1 (SULF1) and sulfatase 2 (SULF2), play pivotal roles in the postsynthetic modifications of heparan sulfate proteoglycans (HSPGs). Consequently, these extracellular enzymes can regulate a variety of downstream pathways by modulating HSPGs function. During the past decades, researchers have detected the expression of SULF1 and SULF2 in most cancers and revealed their roles in tumor progression and metastasis. Herein we reviewed the metastasis steps which SULFs participated in, elucidated the specific roles and mechanisms of SULFs in metastasis process, and discussed the effects of SULFs in different types of cancers. Moreover, we summarized the role of targeting SULFs in combination therapy to treat metastatic cancers, which provided some novel strategies for cancer therapy.

show abstract

“…Ovarian cancer is the fourth most common cancer of female worldwide [156]. Abundant of researches have showed that SULF1 is a known suppressor in ovarian cancers [157].…”

Section: Ovarian Cancermentioning

confidence: 99%

6-O-endosulfatases in tumor metastasis: heparan sulfate proteoglycans modification and potential therapeutic targets

Han

2024

Am J Cancer Res

View full text Add to dashboard Cite

show abstract

“…Prevention and treatment of high-risk HPV cervical infections remain the main approach in combating CC, with the introduction of CC vaccines being a major development in recent years, together with screening technologies ( Rahangdale et al, 2022 ; Rimel et al, 2022 ; Sivars et al, 2022 ; Sun et al, 2022 ; Sabeena, 2023 ). OC, as the seventh most commonly diagnosed female cancer worldwide, poses as the fifth leading cause of cancer-related deaths in women and the most lethal of all gynecological malignancies ( Chen et al, 2023 ; Ye et al, 2023 ). Relatively few conventional screening tools exist for early detection, resulting in over 70% of the cases being diagnosed at advanced stages ( Armbrister et al, 2023 ; Brown et al, 2023 ; Terp et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance

2023

View full text Add to dashboard Cite

Chemotherapy resistance remains a major challenge in the treatment of gynecologic malignancies. Increasing evidence suggests that circular RNAs (circRNAs) play a significant role in conferring chemoresistance in these cancers. In this review, we summarize the current understanding of the mechanisms by which circRNAs regulate chemotherapy sensitivity and resistance in gynecologic malignancies. We also discuss the potential clinical implications of these findings and highlight areas for future research. CircRNAs are a novel class of RNA molecules that are characterized by their unique circular structure, which confers increased stability and resistance to degradation by exonucleases. Recent studies have shown that circRNAs can act as miRNA sponges, sequestering miRNAs and preventing them from binding to their target mRNAs. This can lead to upregulation of genes involved in drug resistance pathways, ultimately resulting in decreased sensitivity to chemotherapy. We discuss several specific examples of circRNAs that have been implicated in chemoresistance in gynecologic cancers, including cervical cancer, ovarian cancer, and endometrial cancer. We also highlight the potential clinical applications of circRNA-based biomarkers for predicting chemotherapy response and guiding treatment decisions. Overall, this review provides a comprehensive overview of the current state of knowledge regarding the role of circRNAs in chemotherapy resistance in gynecologic malignancies. By elucidating the underlying mechanisms by which circRNAs regulate drug sensitivity, this work has important implications for improving patient outcomes and developing more effective therapeutic strategies for these challenging cancers.

show abstract

RNA modification regulators as promising biomarkers in gynecological cancers

Qi,

Li,

Zhou

et al. 2024

Cell Biol Toxicol

View full text Add to dashboard Cite

This review explores the evolving landscape of gynecological oncology by focusing on emerging RNA modification signatures as promising biomarkers for assessing the risk and progression of ovarian, cervical, and uterine cancers. It provides a comprehensive overview of common RNA modifications, especially m6A, and their roles in cellular processes, emphasizing their implications in gynecological cancer development. The review meticulously examines specific m6A regulators including “writers”, “readers”, and “erasers” associated with three gynecological cancer types, discussing their involvement in initiation and progression. Methodologies for detecting RNA modifications are surveyed, highlighting advancements in high-throughput techniques with high sensitivity. A critical analysis of studies identifying m6A regulators as potential biomarkers is presented, addressing their diagnostic or prognostic significance. Mechanistic insights into RNA modification-mediated cancer progression are explored, shedding light on molecular pathways and potential therapeutic targets. Despite current challenges, the review discusses ongoing research efforts, future directions, and the transformative possibility of RNA modifications on early assessment and personalized therapy in gynecological oncology.

show abstract

RNA epigenetic modifications in ovarian cancer: The changes, chances, and challenges

Cited by 8 publications

References 175 publications

6-O-endosulfatases in tumor metastasis: heparan sulfate proteoglycans modification and potential therapeutic targets

6-O-endosulfatases in tumor metastasis: heparan sulfate proteoglycans modification and potential therapeutic targets

Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance

RNA modification regulators as promising biomarkers in gynecological cancers

Contact Info

Product

Resources

About